INVESTOR DAY 2025
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

CVS Health Corporation (the "Company") uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance. These non-GAAP financial measures are provided as supplemental information to the financial measures the Company discloses that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measurements reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share ("EPS") and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. The information on the following pages of this document is forward-looking. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission ("SEC") filings, including those set forth in the Risk Factors section and under the heading "Cautionary Statement Concerning Forward-Looking Statements" in the Company's most recently filed Annual Report on Form 10-K, its most recently filed Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 and its Current Reports on Form 8-K.

You are cautioned not to place undue reliance on the Company's forward-looking statements. The Company's forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

ADJUSTED EARNINGS PER SHARE

GAAP diluted earnings (loss) per share and Adjusted EPS, respectively, are calculated by dividing net income (loss) attributable to CVS Health and adjusted income attributable to CVS Health by the Company's weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income (loss) attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, office real estate optimization charges, certain legacy litigation charges, losses on Accountable Care assets, restructuring charges, the gain on deconsolidation of subsidiary, gains on early extinguishment of debt, as well as the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health.

INVESTOR DAY 2025
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

The following are reconciliations of projected GAAP diluted earnings (loss) per share to projected Adjusted EPS:

	Year Ending December 31,					
	2026E		**2025E**			2024
	Low	**High**	**Low**	**Mid**	**High**	Actual
In millions, except per share amounts	**Per Common Share**					
Net income (loss) attributable to CVS Health (GAAP measure)	**$ 5.94**	**$ 6.14**	**$ (0.32)**	**$ (0.27)**	**$ (0.22)**	$ 3.66
Non-GAAP adjustments:						
Amortization of intangible assets	**1.35**	**1.35**	**1.57**	**1.57**	**1.57**	1.61
Net realized capital (gains) losses	**—**	**—**	**0.05**	**0.05**	**0.05**	(0.09)
Acquisition-related integration costs (1)	**0.06**	**0.06**	**0.12**	**0.12**	**0.12**	0.19
Goodwill impairment (2)	**—**	**—**	**4.50**	**4.50**	**4.50**	—
Health Care Delivery clinic closure charge (3)	**—**	**—**	**0.07**	**0.07**	**0.07**	—
Opioid litigation charges (4)	**—**	**—**	**0.25**	**0.25**	**0.25**	0.08
Office real estate optimization charges (5)	**—**	**—**	**0.01**	**0.01**	**0.01**	0.02
Legacy litigation charges (6)	**—**	**—**	**0.96**	**0.96**	**0.96**	—
Loss on Accountable Care assets (7)	**—**	**—**	**0.23**	**0.23**	**0.23**	—
Restructuring charges (8)	**—**	**—**	**—**	**—**	**—**	0.93
Gain on deconsolidation of subsidiary (9)	**—**	**—**	**(0.38)**	**(0.38)**	**(0.38)**	—
Gain on early extinguishment of debt (10)	**—**	**—**	**—**	**—**	**—**	(0.39)
Tax impact of non-GAAP adjustments (11)	**(0.35)**	**(0.35)**	**(0.46)**	**(0.46)**	**(0.46)**	(0.59)
Adjusted income attributable to CVS Health	**$ 7.00**	**$ 7.20**	**$ 6.60**	**$ 6.65**	**$ 6.70**	$ 5.42
Total baseline adjustments (12)				**(0.45)**		
Baseline Adjusted EPS (12)				**$ 6.20**		
Weighted average diluted shares outstanding	**1,285**	**1,285**	**1,267**	**1,267**	**1,267**	1,262
Adjusted weighted average diluted shares outstanding (non-GAAP) (13)	**1,285**	**1,285**	**1,270**	**1,270**	**1,270**	1,262

ADJUSTED OPERATING INCOME

The Company defines adjusted operating income as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, office real estate optimization charges, certain legacy litigation charges, losses on Accountable Care assets and restructuring charges. The Company's chief operating decision maker ("CODM") uses adjusted operating income as its principal measure of segment performance as it enhances the CODM's ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. The following are reconciliations of projected operating income to projected adjusted operating income:

CONSOLIDATED

	Year Ending December 31,				
	2026E		**2025E**		2024
In millions	**Low**	**High**	**Low**	**High**	Actual
Operating income (GAAP measure)	**$ 13,260**	**$ 13,600**	**$ 4,365**	**$ 4,535**	$ 8,516
Amortization of intangible assets	**1,730**	**1,730**	**2,000**	**2,000**	2,025
Net realized capital (gains) losses	**—**	**—**	**59**	**59**	(117)
Acquisition-related integration costs (1)	**80**	**80**	**150**	**150**	243
Goodwill impairment (2)	**—**	**—**	**5,725**	**5,725**	—
Health Care Delivery clinic closure charge (3)	**—**	**—**	**83**	**83**	—
Opioid litigation charges (4)	**—**	**—**	**320**	**320**	100
Office real estate optimization charges (5)	**—**	**—**	**10**	**10**	30
Legacy litigation charges (6)	**—**	**—**	**1,220**	**1,220**	—
Loss on Accountable Care assets (7)	**—**	**—**	**288**	**288**	—
Restructuring charges (8)	**—**	**—**	**—**	**—**	1,179
Adjusted operating income	**$ 15,070**	**$ 15,410**	**$ 14,220**	**$ 14,390**	$ 11,976

HEALTH CARE BENEFITS SEGMENT

	Year Ending December 31,				
	2026E		**2025E**		2024
In millions	**Low**	**High**	**Low**	**High**	Actual
Operating income (loss) (GAAP measure)	**$ 2,642**	**$ 2,982**	**$ 1,546**	**$ 1,716**	$ (984)
Amortization of intangible assets	**938**	**938**	**1,164**	**1,164**	1,175
Net realized capital losses	**—**	**—**	**1**	**1**	97
Office real estate optimization charges (5)	**—**	**—**	**4**	**4**	19
Adjusted operating income	**$ 3,580**	**$ 3,920**	**$ 2,715**	**$ 2,885**	$ 307
Total baseline adjustments (12)			**(750)**		
Baseline adjusted operating income (12)			**$ 1,965**		

HEALTH SERVICES SEGMENT

	Year Ending December 31,		
	2026E	**2025E**	2024
In millions	**At Least**	**At Least**	Actual
Operating income (GAAP measure)	**$ 6,724**	**$ 156**	$ 6,937
Amortization of intangible assets	**526**	**572**	595
Net realized capital gains	**—**	**(15)**	(289)
Goodwill impairment [2]	**—**	**5,725**	—
Health Care Delivery clinic closure charge [3]	**—**	**83**	—
Legacy litigation charge [6]	**—**	**291**	—
Loss on Accountable Care assets [7]	**—**	**288**	—
Adjusted operating income	**$ 7,250**	**$ 7,100**	$ 7,243

PHARMACY & CONSUMER WELLNESS SEGMENT

	Year Ending December 31,		
	2026E	**2025E**	2024
In millions	**At Least**	**At Least**	Actual
Operating income (GAAP measure)	**$ 5,826**	**$ 4,839**	$ 4,770
Amortization of intangible assets	**264**	**260**	253
Office real estate optimization charges [5]	**—**	**2**	4
Legacy litigation charges [6]	**—**	**929**	—
Restructuring charges [8]	**—**	**—**	747
Adjusted operating income	**$ 6,090**	**$ 6,030**	$ 5,774

ADJUSTED EFFECTIVE INCOME TAX RATE

The following are reconciliations of the projected effective income tax rate to the projected adjusted effective income tax rate:

CONSOLIDATED

	Year Ending December 31,			
	2026E	**2025E**		2024
	Estimated	**Low**	**High**	Actual
Effective income tax rate (GAAP measure)	**25.4 %**	**122.7 %**	**114.5 %**	25.4 %
Impact of non-GAAP adjustments [11]	**(0.1)**	**(97.4)**	**(89.2)**	(0.1)
Adjusted effective income tax rate	**25.3 %**	**25.3 %**	**25.3 %**	25.3 %

Endnotes

(1) The acquisition-related integration costs relate to the acquisitions of Signify Health, Inc. and Oak Street Health, Inc.

(2) The goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.

(3) The Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the planned closure of certain existing Oak Street Health clinics in 2026, as well as associated severance and employee-related costs expected to be incurred.

(4) The opioid litigation charges relate to changes in the Company's accrual related to ongoing opioid litigation matters.

(5) The office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company's evaluation of corporate office real estate space in response to its ongoing flexible work arrangement.

(6) The legacy litigation charges relate to two court decisions associated with the Company's past business practices.

In April 2025, a jury found Omnicare, LLC ("Omnicare") and CVS Health Corporation liable in connection with alleged violations of the federal False Claims Act related to dispensing practices by Omnicare from 2010, prior to its acquisition by the Company in 2015, through 2018. Accordingly, the Company recorded a litigation charge of $387 million during the first quarter of 2025. During the second quarter of 2025, the Company recorded a charge of $542 million, reflecting penalties assessed under the False Claims Act.

In June 2025, a court found certain subsidiaries of CVS Health Corporation liable for damages in connection with a complaint filed in February 2014, in which the government declined to intervene, related to pharmacy benefit management direct and indirect remuneration reporting practices for two clients from 2010 through 2016, which the Company has since modified. In connection with this court decision, the Company recorded a litigation charge of $291 million during the second quarter of 2025.

(7) The loss on Accountable Care assets represents the pre-tax loss on the divestiture of the Company's Medicare Shared Savings Program ("MSSP") operations, which the Company sold in March 2025, as well as costs incurred in connection with the process of winding down the Company's Accountable Care Organization Realizing Equity, Access, and Community Health ("ACO REACH") operations.

(8) The restructuring charges are primarily comprised of a store impairment charge, corporate workforce optimization costs, including severance and employee-related costs, a stock-based compensation charge and other asset impairment and related charges associated with the discontinuation of certain non-core assets. During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it planned to close additional retail stores in 2025, and, accordingly, it recorded a store impairment charge to write down the associated lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company's best estimate of their fair value.

(9) The gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities (collectively, the "Omnicare Entities"). In September 2025, the Omnicare Entities voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code, at which time the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries.

(10) The gain on early extinguishment of debt relates to the Company's repayment of approximately $2.6 billion of its outstanding senior notes in December 2024, pursuant to its tender offer for such senior notes.

(11) Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

(12) In order to enhance the Company's and investors' ability to set growth expectations for future periods, the Company adjusted its full-year 2025 Adjusted EPS and its full-year 2025 Health Care Benefits adjusted operating income to remove certain items that it cannot project for future periods and certain items not expected to reoccur in future periods including: (i) changes in prior years' health care costs estimates; (ii) certain changes in estimates related to prior period revenue recorded in 2025; and (iii) provider liabilities established related to prior periods. For baseline Adjusted EPS, the corresponding tax benefit or expense per share related to the items excluded from baseline Adjusted EPS above has also been removed. When determining the income tax impact of the baseline Adjusted EPS adjustments, the nature of the total baseline adjustments were evaluated to determine whether a discrete adjustment should be made to the baseline income tax provision.

(13) Projected Adjusted EPS for the year ended December 31, 2025 is calculated utilizing projected weighted average diluted shares outstanding, which include potential common shares, as the impact of the potential common shares was dilutive. The potential common shares were excluded from the calculation of projected GAAP loss per share for the year ended December 31, 2025, as the shares would have had an anti-dilutive effect as a result of the projected GAAP net loss.